• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-World Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Mild-to-Moderate Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Retrospective, Single-Arm Clinical Trial [Letter].

作者信息

Aguilar Castañeda Raúl Daniel

机构信息

Universidad Autónoma de San Luis Potosí, Facultad de Medicina, San Luis Potosí, México.

出版信息

Diabetes Metab Syndr Obes. 2024 Aug 28;17:3215-3216. doi: 10.2147/DMSO.S489805. eCollection 2024.

DOI:10.2147/DMSO.S489805
PMID:39220802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11366235/
Abstract
摘要

相似文献

1
Real-World Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Mild-to-Moderate Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Retrospective, Single-Arm Clinical Trial [Letter].胰高血糖素样肽-1受体激动剂对2型糖尿病患者轻度至中度糖尿病肾病的真实世界临床疗效：一项回顾性单臂临床试验[信函]
Diabetes Metab Syndr Obes. 2024 Aug 28;17:3215-3216. doi: 10.2147/DMSO.S489805. eCollection 2024.
2
Real-World Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Mild-to-Moderate Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Retrospective, Single-Arm Clinical Trial.胰高血糖素样肽-1受体激动剂对2型糖尿病患者轻度至中度糖尿病肾病的真实世界临床疗效：一项回顾性单臂临床试验。
Diabetes Metab Syndr Obes. 2024 Aug 1;17:2913-2921. doi: 10.2147/DMSO.S472968. eCollection 2024.
3
Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study.在北马其顿，接受胰高血糖素样肽-1 受体激动剂治疗的 2 型糖尿病患者每周一次使用司美格鲁肽的真实世界数据：MIRAGE 研究。
Diabetes Res Clin Pract. 2023 Dec;206:111018. doi: 10.1016/j.diabres.2023.111018. Epub 2023 Nov 14.
4
Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.胰高血糖素样肽-1 受体激动剂治疗慢性肾脏病伴 2 型糖尿病患者的疗效及其对肾脏的影响评价。
J Diabetes. 2019 Dec;11(12):938-948. doi: 10.1111/1753-0407.12969. Epub 2019 Aug 14.
5
No Differences in Kidney Function Decline Between People With Type 2 Diabetes Starting a Sodium-Glucose Cotransporter 2 Inhibitor or a Glucagon-like Peptide-1 Receptor Agonist: A Real-world Retrospective Comparative Observational Study.在开始使用钠-葡萄糖共转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂的 2 型糖尿病患者中，肾功能下降无差异：一项真实世界回顾性比较观察性研究。
Clin Ther. 2024 Nov;46(11):828-834. doi: 10.1016/j.clinthera.2024.04.009. Epub 2024 Jul 4.
6
HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.在真实世界环境中，接受坎格列净或胰高血糖素样肽-1 受体激动剂治疗的 2 型糖尿病患者的 HBA1C 控制和成本效益。
Endocr Pract. 2018 Mar;24(3):273-287. doi: 10.4158/EP-2017-0066.
7
Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial).改善 1 型糖尿病的肥胖治疗（OTID）：胰高血糖素样肽 1 类似物和钠-葡萄糖共转运蛋白 2 抑制剂联合治疗的随机对照试验——改善 1 型糖尿病的肥胖治疗（OTID 试验）方案。
Trials. 2024 Feb 16;25(1):129. doi: 10.1186/s13063-024-07930-3.
8
Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.用于治疗糖尿病肾病的 SGLT2 抑制剂和 GLP-1 受体激动剂的处方决策算法。
Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1678-1688. doi: 10.2215/CJN.02690320. Epub 2020 Jun 9.
9
Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.胰高血糖素样肽-1 受体激动剂在 2 型糖尿病患者中的疗效和安全性：一项回顾性真实世界研究的证据。
Front Endocrinol (Lausanne). 2024 Mar 8;15:1347684. doi: 10.3389/fendo.2024.1347684. eCollection 2024.
10
Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression.胰高血糖素样肽-1激动剂在延缓慢性肾脏病进展方面的新证据。
Curr Opin Nephrol Hypertens. 2024 May 1;33(3):331-336. doi: 10.1097/MNH.0000000000000976. Epub 2024 Feb 23.

本文引用的文献

1
Real-World Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Mild-to-Moderate Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Retrospective, Single-Arm Clinical Trial.胰高血糖素样肽-1受体激动剂对2型糖尿病患者轻度至中度糖尿病肾病的真实世界临床疗效：一项回顾性单臂临床试验。
Diabetes Metab Syndr Obes. 2024 Aug 1;17:2913-2921. doi: 10.2147/DMSO.S472968. eCollection 2024.
2
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.KDIGO 2022慢性肾脏病糖尿病管理临床实践指南
Kidney Int. 2022 Nov;102(5S):S1-S127. doi: 10.1016/j.kint.2022.06.008.
3
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.在研究胰高血糖素样肽-1受体激动剂的临床试验中报告为不良事件的恶心、呕吐和腹泻的发生情况：已发表临床试验的系统分析
Diabetes Obes Metab. 2017 Mar;19(3):336-347. doi: 10.1111/dom.12824. Epub 2016 Dec 19.